Fever News and Research

RSS

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.

11 Dec 2013

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013.

11 Dec 2013

Restricting antibiotics use unlikely to stop spread of drug resistance in typhoid fever

Restricting the use of antibiotics is unlikely to stop the spread of drug resistance in typhoid fever, according to a study funded by the Wellcome Trust and published in the journal eLife.

10 Dec 2013

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.

9 Dec 2013

Malaria cases in the U.S. rising due to international travel, inadequate use of prevention methods

The number of malaria cases in the United States is rising, a trend that can be linked to the increasing amount of international travel and inadequate use of prevention methods.

9 Dec 2013

Atonomics reaches agreement to advance development of diagnostic test for lifestyle diseases

Atonomics announces today that it has entered into an agreement with Omron Healthcare, which will enable Atonomics to advance the development of the AtolyzerConsumer device for advanced diagnostic testing of lifestyle diseases in a consumer pharmacy setting. As part of the transaction Omron Healthcare is taking a minority equity stake in Atonomics.

9 Dec 2013

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

A series of advancements in genetically engineered cell therapies demonstrate early efficacy and safety in patients with blood disorders for whom standard treatments have been unsuccessful, according to data showcased today during the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans.

9 Dec 2013

Prolonged febrile seizures can affect pediatric patients

A long-standing hypothesis holds that prolonged febrile (fever induced) seizures, the most common form of childhood convulsive status epilepticus, cause mesial temporal sclerosis. CSE is a single seizure, or two or more seizures between which consciousness is not regained, lasting for more than 30 minutes.

9 Dec 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

College students not only bring dirty socks but also mononucleosis to home

One of the hallmarks of heading home for winter break is the enormous amounts of laundry college students bring as a welcome home present for Mom and Dad. But the dirty socks might not be the only unwelcome guest they transport home. They might also bring mononucleosis, better known as mono.

6 Dec 2013

Measles still poses threat to domestic and global health security

Fifty years after the approval of an extremely effective vaccine against measles, one of the world's most contagious diseases, the virus still poses a threat to domestic and global health security.

5 Dec 2013

EMA expands administration options for Hizentra

CSL Behring UK Ltd announced today that the European Medicines Agency (EMA) has expanded the administration options for Hizentra®▼, human normal immunoglobulin, SCIg, 20% liquid, to include dosing once every two weeks (fortnightly).

5 Dec 2013

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

4 Dec 2013

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.

2 Dec 2013

Longer looks: Providing dental care in rural Alaska; the after-effects of the ICU; cure for allergies

Aniak, Alaska, is a Yu'pik village of 500 people on the Yukon-Kuskokwim delta, about 400 miles northwest of Anchorage. It is in this special and isolated community where I practice as a dental therapist, trained and certified to deliver some, but not all, types of dental care. Dental therapists have been practicing in Alaska for nine years and now provide routine dental care to 40,000 Native Alaskans. In the United States about forty-seven million people live in areas where there is a shortage of dentists, and millions more can't afford to see them. For so many Americans, even the most basic dental care is out of reach. Yet right here in Alaska, I think we've found part of the solution (Conan Murat, November, 2013).

28 Nov 2013

Probiotic drink changes reaction of cells lining nasal passages of hay fever sufferers

A study has shown that a daily probiotic drink changed how cells lining the nasal passages of hay fever sufferers reacted to a single out-of-season challenge. However, it did not lead to significant changes in hay fever symptoms, although this challenge test may not have accurately represented natural allergen exposure.

27 Nov 2013

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets.

27 Nov 2013

Researchers find that hay fever and allergies make migraines worse

People with migraine who also battle allergies and hay fever (rhinitis) endure a more severe form of headaches than their peers who struggle with migraine, but aren't affected by the seasonal or year-round sniffles, according to researchers from the University of Cincinnati, Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University and Vedanta Research.

26 Nov 2013

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency's: Committee for Medicinal Products for Human Use has adopted a positive opinion for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.

25 Nov 2013

NeutroPhase irrigation therapy and NPWT help treat severe flesh eating and wound infections

NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced the publication of a scientific paper by Dr. John R. Crew of Seton Medical Center, Daly City, California, describing the first use of adjunctive NeutroPhase irrigation therapy in conjunction with Negative Pressure Wound Therapy to successfully manage the severely-infected wound in the arm of a patient with life-threatening 'flesh-eating' disease.

20 Nov 2013

Fever News and Research

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Restricting antibiotics use unlikely to stop spread of drug resistance in typhoid fever

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Malaria cases in the U.S. rising due to international travel, inadequate use of prevention methods

Atonomics reaches agreement to advance development of diagnostic test for lifestyle diseases

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

Prolonged febrile seizures can affect pediatric patients

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

College students not only bring dirty socks but also mononucleosis to home

Measles still poses threat to domestic and global health security

EMA expands administration options for Hizentra

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Longer looks: Providing dental care in rural Alaska; the after-effects of the ICU; cure for allergies

Probiotic drink changes reaction of cells lining nasal passages of hay fever sufferers

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Researchers find that hay fever and allergies make migraines worse

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

NeutroPhase irrigation therapy and NPWT help treat severe flesh eating and wound infections

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News